{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-023806","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.238832+00:00","generated_at":"2026-06-06T02:28:31.032365+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NRXP amends $11M convertible note; $1.1M cash due Feb 12, then $400K/month through July","bullets":["Third Amendment to $11.02M convertible note with Streeterville Capital executed Feb 9, 2024.","Company to pay $1.1M cash on Feb 12, 2024; monthly $400K cash minimum from Feb 29 to July 31, 2024.","During first three months, Streeterville cannot redeem above monthly minimum; after, up to $1M/month subject to cap.","Company can pay monthly minimum in shares if Streeterville submits redemption notices; otherwise cash required.","Outstanding balance after July 31, 2024 must be fully paid in cash by Aug 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-023806","json":"https://secwatch.observer/filing/0001104659-24-023806.json","markdown":"https://secwatch.observer/filing/0001104659-24-023806.md","text":"https://secwatch.observer/filing/0001104659-24-023806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/0001104659-24-023806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/tm246184d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:28:31.032365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77a1a9be11cef43600b8c22a84b4892078090e4e","claim":"NRX Pharmaceuticals, Inc. amended Amendment #3 to Convertible Promissory Note with Streeterville Capital, LLC valued at $1,100,000 (effective 2024-02-09).","evidence_excerpt":"On February 9, 2024 NRX Pharmaceuticals, Inc. (the “Company”) entered into Amendment #3 to Convertible Promissory Note (the “Third Amendment”), with Streeterville Capital, LLC (“Streeterville”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/0001104659-24-023806-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"$1,100,000"},{"label":"Effective","value":"2024-02-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}